VERTEX PHARMACEUTICALS INC / MA

This proxy statement contains forward-looking statements. Forward-looking statements are not purely historical and may be

accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,”

“estimates,” and other words and terms of similar meaning. Such statements may include, without limitation, statements regarding: our

research and development strategy, including with respect to delivering transformative medicines at high rates of speed and success

and enabling leadership in selected disease areas, our marketed products and pipeline therapies, particularly with respect to benefits,

safety, and expansion into younger patients and additional geographies, potential regulatory submissions and approvals, expected

clinical development plans and timing, continued significant investment in internal and external innovation, and expectations regarding

the ongoing diversification of our commercialization efforts, our beliefs, expectations, plans and expectations with respect to the

potential near-term launch of povetacicept for IgAN and with respect to the continued commercial progress for CASGEVY for the

treatment of SCD and TDT, ALYFTREK for the treatment of CF, and JOURNAVX for the treatment of moderate-to-severe acute pain,

including with respect to continued prescription and revenue growth for JOURNAVX in 2026, expectations for the data that will be

generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or

support regulatory filings, or accelerate regulatory approval, plans to share data from the interim analysis of inaxaplin for the treatment

of AMKD in late 2026 or early 2027, expectations to complete enrollment in both Phase 3 clinical trials evaluating suzetrigine for the

treatment ofdiabetic peripheral neuropathy by the end of 2026, beliefs regarding the temporary postponement in the Phase 1/2/3 study

of zimislecel for the treatment of T1D and plans for the ongoing internal manufacturing analysis, and expectations to complete the

Phase 2 portion of the clinical trial evaluating povetacicept for the treatment of pMN and initiate the Phase 3 portion in mid-2026. While

we believe the forward-looking statements contained in this proxy statement are accurate, these forward-looking statements represent

our beliefs only as of the date of this proxy statement. There are a number of risks and uncertainties that are difficult to predict and

could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and

uncertainties include, among other things, that the company’s expectations regarding its future financial performance may be incorrect

(including because one or more of the company’s assumptions underlying its expectations may not be realized), that regulatory

submissions or approvals may not occur on the anticipated timeline, or at all, that we may be unable to launch and commercialize

povetacicept as a treatment for IgAN or to further successfully commercialize ALYFTREK as a treatment for CF, JOURNAVX as a

treatment for acute pain, and CASGEVY as a treatment for SCD and TDT, that data from clinical trials or preclinical testing, especially if

based on a limited number of patients, may not be indicative of final results, that data from the company’s developmental programs

may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or

other reasons, that regulatory authorities may not approve regulatory filings for our pipeline products on a timely basis, or at all, that

external factors may have different or more significant impacts on the company's business or operations than the company currently

expects, and other risks listed under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December

31, 2025, filed with the SEC on February 13, 2026, and available through the company’s website at www.vrtx.com. You should not

place undue reliance on these statements, or any data presented. We disclaim any obligation to update the information contained in

this proxy statement as new information becomes available, except as required by law.

Website references are provided throughout this document for convenience. The content on the referenced website does not constitute

part of and is not incorporated by reference into this proxy statement.